| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anthony S Rauhut, Isaac J Zentner, Stacey K Mardekian, Jason B Tanenbau. Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine. Physiology & behavior. vol 93. issue 1-2. 2008-04-22. PMID:17889041. |
to further examine the relationship between anhedonia, clinical depression and nicotine reward, the present experiment determined if wistar kyoto (wky) rats, an animal model of clinical depression, differed from wistar rats in nicotine conditioned place preference (cpp). |
2008-04-22 |
2023-08-12 |
rat |
| Anthony S Rauhut, Isaac J Zentner, Stacey K Mardekian, Jason B Tanenbau. Wistar Kyoto and Wistar rats differ in the affective and locomotor effects of nicotine. Physiology & behavior. vol 93. issue 1-2. 2008-04-22. PMID:17889041. |
collectively, these results suggest that wky rats show deficits in nicotine reward and specific aversive drug stimuli compared to wistar rats. |
2008-04-22 |
2023-08-12 |
rat |
| Jamie L Wilkinson, Rick A Bevin. Intravenous nicotine conditions a place preference in rats using an unbiased design. Pharmacology, biochemistry, and behavior. vol 88. issue 3. 2008-04-09. PMID:17888504. |
the place conditioning task, a widely used pre-clinical model to study drug reward, has lead to mixed results in rats when nicotine was administered subcutaneously or intraperitoneally; intravenously administered nicotine has not been examined. |
2008-04-09 |
2023-08-12 |
rat |
| Yann S Mineur, Marina R Picciott. Genetics of nicotinic acetylcholine receptors: Relevance to nicotine addiction. Biochemical pharmacology. vol 75. issue 1. 2008-02-26. PMID:17632086. |
genetic engineering studies in mice have identified a number of subunits that are critical for the ability of nicotine to activate the reward system in the brain, consisting of the dopaminergic cell bodies in the ventral tegmental area and their terminals in the nucleus accumbens and other portions of the mesolimbic system. |
2008-02-26 |
2023-08-12 |
mouse |
| Michael B Steinberg, Jonathan Fould. Rimonabant for treating tobacco dependence. Vascular health and risk management. vol 3. issue 3. 2008-02-25. PMID:17703638. |
the endocannabinoid system has been linked to the nicotine reward pathways in animal models. |
2008-02-25 |
2023-08-12 |
Not clear |
| Jonathan P Britt, Daniel S McGehe. Presynaptic opioid and nicotinic receptor modulation of dopamine overflow in the nucleus accumbens. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 28. issue 7. 2008-02-25. PMID:18272687. |
these observations reveal remarkable mechanistic overlap between the effects of nicotine and opiates within the dopamine reward pathway. |
2008-02-25 |
2023-08-12 |
Not clear |
| H van Bronswijk, E A Dubois, F G Zitman, A F Cohe. [New drugs; varenicline]. Nederlands tijdschrift voor geneeskunde. vol 151. issue 45. 2008-01-22. PMID:18062594. |
nicotine acts in the brain by releasing dopamine in the mesolimbic pathway which results in a reward effect and in dependence when used chronically. |
2008-01-22 |
2023-08-12 |
Not clear |
| H van Bronswijk, E A Dubois, F G Zitman, A F Cohe. [New drugs; varenicline]. Nederlands tijdschrift voor geneeskunde. vol 151. issue 45. 2008-01-22. PMID:18062594. |
varenicline can be used for quitting smoking because of two mechanisms: it acts as a partial agonist and thus reduces the symptoms of craving when quitting smoking, and it has antagonistic actions by binding the receptor instead of nicotine and therefore decreases the reward effect of nicotine. |
2008-01-22 |
2023-08-12 |
Not clear |
| Patrik Maurer, Martin F Bachman. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert opinion on investigational drugs. vol 16. issue 11. 2007-11-13. PMID:17970637. |
nicotine is the major addictive component of tobacco and acts on the reward system in the brain. |
2007-11-13 |
2023-08-12 |
Not clear |
| Matthias E Liechti, Athina Marko. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17601493. |
metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. |
2007-11-06 |
2023-08-12 |
rat |
| Matthias E Liechti, Athina Marko. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17601493. |
we hypothesized that an mglu2/3 receptor agonist would have negative effects on nicotine withdrawal because mglu2/3 receptor antagonists have previously been shown to attenuate nicotine withdrawal-induced reward deficits, while an mglu2/3 receptor agonist precipitated withdrawal-like reward deficits in rats dependent on nicotine. |
2007-11-06 |
2023-08-12 |
rat |
| Matthias E Liechti, Athina Marko. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17601493. |
to test this hypothesis, we assessed the effects of the mglu2/3 receptor agonist ly379268 on brain reward deficits associated with spontaneous nicotine withdrawal in rats. |
2007-11-06 |
2023-08-12 |
rat |
| Matthias E Liechti, Athina Marko. Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17601493. |
ly379268 administration produced reward deficits in animals "withdrawing" from chronic saline administration and only tended to aggravate nicotine withdrawal-induced reward deficits in rats previously treated with nicotine. |
2007-11-06 |
2023-08-12 |
rat |
| Linda P Dwoskin, B Matthew Joyce, Guangrong Zheng, Nichole M Neugebauer, Vamshi K Manda, Paul Lockman, Roger L Papke, Michael T Bardo, Peter A Crook. Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD). Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17727820. |
one strategy is to develop subtype-selective nicotinic receptor (nachr) antagonists that inhibit nicotine-evoked dopamine (da) release, the primary neurotransmitter involved in nicotine reward. |
2007-11-06 |
2023-08-12 |
rat |
| Huibert D Mansvelder, Zara M Fagen, Ben Chang, Robert Mitchum, Daniel S McGehe. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17868653. |
here we show that clinical concentrations of bupropion inhibit nicotine's stimulatory effects on brain reward areas. |
2007-11-06 |
2023-08-12 |
Not clear |
| Huibert D Mansvelder, Zara M Fagen, Ben Chang, Robert Mitchum, Daniel S McGehe. Bupropion inhibits the cellular effects of nicotine in the ventral tegmental area. Biochemical pharmacology. vol 74. issue 8. 2007-11-06. PMID:17868653. |
many drugs of abuse, including nicotine, stimulate dopamine (da) release in the mesoaccumbens reward system. |
2007-11-06 |
2023-08-12 |
Not clear |
| Anne-Sophie Villégier, Shahrdad Lotfipour, James D Belluzzi, Frances M Lesli. Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat. Psychopharmacology. vol 193. issue 4. 2007-10-23. PMID:17486319. |
nicotine, the psychoactive component in tobacco, is generally believed to be the main cause of reward and addiction. |
2007-10-23 |
2023-08-12 |
rat |
| Anne-Sophie Villégier, Shahrdad Lotfipour, James D Belluzzi, Frances M Lesli. Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat. Psychopharmacology. vol 193. issue 4. 2007-10-23. PMID:17486319. |
however, tobacco smoke contains thousands of constituents, some of which may interact with nicotine to enhance reward. |
2007-10-23 |
2023-08-12 |
rat |
| Anne-Sophie Villégier, Shahrdad Lotfipour, James D Belluzzi, Frances M Lesli. Involvement of alpha1-adrenergic receptors in tranylcypromine enhancement of nicotine self-administration in rat. Psychopharmacology. vol 193. issue 4. 2007-10-23. PMID:17486319. |
the aim of the present study was to evaluate the role of noradrenergic systems in mediating this enhancement of nicotine reward. |
2007-10-23 |
2023-08-12 |
rat |
| Pia Steensland, Jeffrey A Simms, Joan Holgate, Jemma K Richards, Selena E Bartlet. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking. Proceedings of the National Academy of Sciences of the United States of America. vol 104. issue 30. 2007-09-10. PMID:17626178. |
we show that acute administration of varenicline, in doses reported to reduce nicotine reward, selectively reduced ethanol but not sucrose seeking using an operant self-administration drinking paradigm and also decreased voluntary ethanol but not water consumption in animals chronically exposed to ethanol for 2 months before varenicline treatment. |
2007-09-10 |
2023-08-12 |
Not clear |